RxDoctor Payments Data

Donna Morgan, MD

Interventional Pain Medicine · Eugene, ORNPI 1184649303

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,781 of the $9,370 with a category attached, or 61.7%. 18 manufacturers reported payments, led by Boston Scientific at 31.4% of the total. Reporting peaked in 2019 at $3,234 and has fallen 96.3% since, to $120 in 2025.

$9,370in general payments, 2019–2025

Across 230 payments — averaging $40.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Relievant Medsystems, Inc.$2K
  • Nevro Corp.$2K
  • Medtronic$683
  • Nalu Medical, Inc.$585
  • Vertos Medical, Inc.$189
  • plus $825 from 12 others

What the payments were for

  • Travel & lodging$3,54838%
  • Food & beverage$5,78162%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,370 in reported general payments places this provider in the 55th percentile of 22 interventional pain medicine providers in Oregon.

See all interventional pain medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$118,704
Medicare patients
198
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate18$8,855
Buprenorphine27$8,038
Oxycodone Hcl272$5,192
Fentanyl44$5,030
Buprenorphine Hcl53$5,006
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen182$4,122
Hydromorphone Hcl125$3,029
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen77$2,443
Gabapentin111$2,256
Tizanidine Hcl126$2,071
Celecoxib16$1,655
Morphine Sulfate ErMorphine Sulfate61$1,617
Methadone Hcl79$1,472
Pregabalin59$1,017
Baclofen45$978

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →